Section Arrow
Quote
GLUE.NASDAQ
- Monte Rosa Therapeutics
Quotes are at least 15-min delayed:2026/04/14 19:25 EDT
After Hours
Last
 17.5
0 (0.00%)
Bid
17.2
Ask
17.53
High 18.1763 
Low 17.5 
Volume 123.45K 
Regular Hours (Closed)
Last
 17.5
-0.05 (-0.28%)
Day High 
18.06 
Prev. Close
17.55 
1-M High
18.5 
Volume 
754.86K 
Bid
17.2
Ask
17.53
Day Low
17.485 
Open
17.72 
1-M Low
14.2 
Market Cap 
1.40B 
Currency 美元 
P/E 50.19 
%Yield -- 
10-SMA 17.05 
20-SMA 16.34 
50-SMA 17.69 
52-W High 25.77 
52-W Low 3.51 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.46/-1.28
Enterprise Value
1.44B
Balance Sheet
Book Value Per Share
2.91
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
123.67M
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
HOTHHoth Therapeutics0.6459+0.134+26.18%-- 
After Hours 0.65 +0.0041 +0.63%
ALLOAllogene Therapeutics2.28-0.78-25.49%-- 
After Hours 2.19 -0.09 -3.95%
VRAXVirax Biolabs Group Limited0.148-0.0184-11.06%-- 
After Hours 0.1384 -0.0096 -6.49%
CMNDClearmind Medicine Inc.0.91-0.52-36.36%-- 
After Hours 0.8558 -0.0542 -5.96%
REPLReplimune Group1.95+0.25+14.71%-- 
After Hours 1.9001 -0.0499 -2.56%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.